What drug is tepotinib? Comprehensive analysis of mechanism of action and targets

Tepotinib is an innovative targeted anti-cancer drug specifically used to treat patients with non-small cell lung cancer (NSCLC) carrying METex14 skipping mutations. This gene mutation is considered to be one of the important driving factors for tumor occurrence and progression, and Tepotinib achieves its anti-tumor effect by precisely inhibiting this molecular pathway. The drug is one of the first MET inhibitors approved for the treatment of this mutant type of lung cancer, embodying a new breakthrough in precision medicine in the treatment of lung cancer. Its trade name is Tepmetko, which has been launched in the United States, Japan and some European countries, and has gradually attracted great attention from the global medical community.

In terms of its mechanism of action, Tepotinib is an oral, small molecule tyrosine kinase inhibitor (TKI) whose main target is the MET (mesenchymal-epithelial transition factor) receptor. MET is a receptor-type tyrosine kinase that is widely expressed in various tissues of the human body and is responsible for regulating cell proliferation, migration, and differentiation under normal circumstances. However, when a skipping mutation in exon 14 of the MET gene occurs, it will cause the MET protein degradation mechanism to fail, causing it to continue to be overexpressed on the cell surface, thereby abnormally activating downstream signaling pathways, such as RAS/MAPK, PI3K/AKT and STAT3, etc., thereby promoting unlimited proliferation of cancer cells, inhibiting apoptosis, and enhancing invasion ability. This mutation has a certain incidence in non-small cell lung cancer, especially in the elderly or non-smokers, and often has a poor prognosis and lacks effective treatments.

The original intention of developing Tepotinib was to target this kind of targeted mutations with clear causes but scarce treatment options. It effectively inhibits MET-mediated signaling in cancer cells by highly specifically binding to the MET kinase domain and blocking its phosphorylation process. It is worth noting that compared with traditional chemotherapy or non-selective targeted therapy, tepotinib not only improves the accuracy of treatment, but also significantly reduces the toxic side effects on normal cells, which is a typical embodiment of the concept of targeted therapy.

In addition, Tepotinib also exhibits good pharmacokinetic characteristics and good tissue penetration, and has even been observed to have a certain efficacy in lung cancer patients with brain metastases, which is difficult to achieve with many traditional drugs. Its once-daily oral dosing regimen improves patient compliance and makes long-term treatment more feasible. It received FDA priority review and "breakthrough therapy designation" in an international multi-center trial based on its outstanding performance in MET-mutant lung cancer.

In clinical application, tepotinib usually needs to be combined with genetic testing for patient screening.It is effective in patients with lung cancer who are positive for MET exon 14 skipping mutations. Therefore, molecular characterization must be clarified by liquid biopsy or tissue biopsy before treatment. This "target first, personalized customization" approach not only improves the efficiency of drug utilization, but also reduces the risk of blind drug use.

From the perspective of the development trend of anti-tumor drugs, the launch of tepotinib represents a shift in lung cancer treatment from traditional chemotherapy to highly personalized treatment. Compared with other MET inhibitors (such as cabozantinib and crizotinib), tepotinib has better performance in terms of selectivity, safety and sustained efficacy.

Reference materials:https://www.tepotinib.com/